## **QIBA Process Committee Meeting**

April 18, 2023, at 2 pm (CT)

Meeting Summary

Attendees:

Kevin O'Donnell, MASc (Chair)

Michael Boss, PhD (Vice Chair)

Caroline Chung, MD

RSNA Staff:

Joe Koudelik

Nancy Obuchowski, PhD

Julie Lisiecki

## **Next Steps / Action Items:**

## Availability of Data Repositories for QIBA Use

- Need to assess availability of large repositories that are intended for public or semi-public access
- MIDRC, NIH Imaging Data Commons, TCIA and the ACR Data Analysis and Research Toolkit (DART) compared
- MIDRC planning to expand beyond COVID cases by year 2 or 3

# Topics for Process Committee Updates During the May 9th Steering Committee Meeting

- Proposal made to initiate a five-year review/update process for all QIBA Profiles
- Simplifying the QIBA language for ease of use, especially non-QIBA members
- Mr. O'Donnell to bring proposal to the Steering Committee meeting (May 9) for discussion
- Process Committee leaders to follow up offline regarding presentation materials

#### **Review and Update of Stage 4 Trial Requirements**

- Two or more procedurally independent clinical sites (in terms of training, guidelines, policies, etc.) engaging technologists, physicist, and radiologists will be required, though additional sites may be encouraged
- A requirement of one site not involved in Stage 3 feasibility testing was suggested
- At least two scanner vendors to be represented across all participating sites
- Proposed baseline requirement of at least four different scanner devices (several of which could be the same vendor/model/version)
- Prospective study sample size to include at least thirty-five test-retest subjects
- Balance in sample size between sites and scanners would be optimal, but no strict balance is needed
  - o Balance / representation across models and devices not required but would be nice to have

## Requirements for Test and Retest (Coffee Break) Scanning

- If different scanner models are allowed, patients would need to be moved and scanned on the second platform by a different technologist
- BCs to identify the top two meaningful sources of residual variability between test/retest to help understand performance requirements for both steps
- Mr. O'Donnell to work on wording for requirements related to subject removal from the table between scans

Mr. O'Donnell to circulate the latest version of the Stage 4 Study Requirements and Considerations document for feedback

#### Next Process Cmte Meeting on Tuesday, May 2, 2023, at 2 p.m. CT

• Review of Stage 4 requirements to resume